Concord Biotech Limited has informed the Exchange regarding ' Successful Completion Of EU GMP Inspection'.
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Smallcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Concord Biotech announced that it has successfully completed the European Union Good Manufacturing Practices (EU GMP) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Dholka, Gujarat. The inspection was carried out over five days, from July 14 to July 18, 2025. The company highlighted this as a reflection of its commitment to maintaining the highest standards of quality, safety, and regulatory compliance. EU GMP certification is a key regulatory milestone that allows the company to supply APIs to European markets.
This is a positive development for shareholders as EU GMP certification strengthens Concord Biotech's credibility and eligibility to supply APIs to European pharma companies. It could support future revenue growth and expand the company's global market reach.